Labcorp Holdings Inc. (LH)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $30.08B
Last updated: Nov 17, 2026 at 11:06 AM ET
Labcorp Holdings Inc. (LH) Earnings: Report Dates and Results
Labcorp Holdings (LH) is expected to report earnings on Feb 15, 2027. In the quarter ended Sep 30, 2026, Labcorp Holdings reported EPS of $4.78, above the $4.65 estimate. It beat the EPS estimate in each of the last 13 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
LH has an expected report date of Feb 15, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 14.3% above the $4.07 reported for the quarter ended Dec 31, 2025.
LH Earnings Call
The latest LH earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, LH beat 35, missed 3 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $3.81B, up 7.0% from $3.56B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $4.78 | $4.65 | $4.49 - $4.69 | +2.80% | Beat | +14.4% | 14 | 0 up, 2 down | Oct 28, 2026 | $3.81B |
| Jun 30, 2026 | $4.99 | $4.79 | $4.68 - $4.82 | +4.18% | Beat | +14.7% | 13 | 0 up, 2 down | Jul 30, 2026 | $3.73B |
| Mar 31, 2026 | $4.25 | $4.12 | $3.96 - $4.35 | +3.16% | Beat | +10.7% | 14 | 2 up, 3 down | Apr 30, 2026 | $3.54B |
| Dec 31, 2025 | $4.07 | $3.94 | $3.79 - $4.00 | +3.30% | Beat | +18.0% | 15 | 2 up, 0 down | Feb 17, 2026 | $3.52B |
| Sep 30, 2025 | $4.18 | $4.14 | $4.04 - $4.34 | +0.97% | Beat | +19.4% | 15 | 4 up, 0 down | Oct 28, 2025 | $3.56B |
| Jun 30, 2025 | $4.35 | $4.16 | $4.08 - $4.26 | +4.57% | Beat | +10.4% | 15 | 2 up, 1 down | Jul 24, 2025 | $3.53B |
| Mar 31, 2025 | $3.84 | $3.73 | $3.52 - $3.89 | +2.95% | Beat | +4.3% | 15 | N/A | Apr 29, 2025 | $3.35B |
| Dec 31, 2024 | $3.45 | $3.39 | $3.26 - $3.50 | +1.77% | Beat | +4.5% | 14 | 3 up, 0 down | Feb 6, 2025 | $3.33B |
| Sep 30, 2024 | $3.50 | $3.49 | $3.31 - $3.65 | +0.29% | Beat | +3.6% | 15 | 1 up, 1 down | Oct 24, 2024 | $3.28B |
| Jun 30, 2024 | $3.94 | $3.77 | $3.69 - $3.85 | +4.51% | Beat | +15.2% | 15 | 0 up, 0 down | Aug 1, 2024 | $3.22B |
| Mar 31, 2024 | $3.68 | $3.48 | $3.30 - $3.59 | +5.75% | Beat | -3.7% | 15 | 0 up, 2 down | Apr 25, 2024 | $3.18B |
| Dec 31, 2023 | $3.30 | $3.26 | $3.11 - $3.40 | +1.23% | Beat | -20.3% | 14 | 0 up, 0 down | Feb 15, 2024 | $3.03B |
| Sep 30, 2023 | $3.38 | $3.33 | $3.11 - $3.43 | +1.50% | Beat | -27.8% | 13 | 0 up, 2 down | Oct 26, 2023 | $3.06B |
| Jun 30, 2023 | $3.42 | $3.45 | $3.43 - $3.77 | -0.87% | Miss | -31.0% | 5 | 0 up, 1 down | Jul 27, 2023 | $3.03B |
| Mar 31, 2023 | $3.82 | $3.96 | $3.66 - $4.33 | -3.54% | Miss | -37.5% | 13 | 0 up, 1 down | Apr 25, 2023 | $3.04B |
| Dec 31, 2022 | $4.14 | $4.14 | N/A | 0.00% | In line | -38.8% | 13 | 0 up, 1 down | Feb 16, 2023 | $2.17B |
| Sep 30, 2022 | $4.68 | $4.68 | $4.52 - $5.17 | 0.00% | In line | -31.4% | 14 | 2 up, 1 down | Oct 27, 2022 | $2.87B |
| Jun 30, 2022 | $4.96 | $4.68 | $4.41 - $5.09 | +5.98% | Beat | -19.1% | 14 | 4 up, 0 down | Jul 28, 2022 | $2.92B |
| Mar 31, 2022 | $6.11 | $6.00 | $4.46 - $6.85 | +1.83% | Beat | -30.5% | 14 | 2 up, 1 down | Apr 28, 2022 | $3.90B |
| Dec 31, 2021 | $6.77 | $5.80 | $5.07 - $6.87 | +16.72% | Beat | -35.9% | 13 | 3 up, 0 down | Feb 10, 2022 | $1.07B |
| Sep 30, 2021 | $6.82 | $4.92 | $4.22 - $6.76 | +38.62% | Beat | -18.9% | 14 | N/A | Oct 28, 2021 | $4.06B |
| Jun 30, 2021 | $6.13 | $5.62 | $4.83 - $6.35 | +9.07% | Beat | +138.5% | 13 | N/A | Jul 29, 2021 | $3.84B |
| Mar 31, 2021 | $8.79 | $7.49 | $6.17 - $8.97 | +17.36% | Beat | +270.9% | 14 | N/A | Apr 29, 2021 | $4.16B |
| Dec 31, 2020 | $10.56 | $8.07 | $6.44 - $9.33 | +30.86% | Beat | +269.2% | 14 | N/A | Feb 11, 2021 | $4.49B |
| Sep 30, 2020 | $8.41 | $5.32 | $3.73 - $6.53 | +58.08% | Beat | +190.0% | 15 | N/A | Oct 27, 2020 | $3.90B |
| Jun 30, 2020 | $2.57 | $0.99 | -$0.08 - $2.10 | +159.60% | Beat | -12.3% | 13 | N/A | Jul 28, 2020 | $2.77B |
| Mar 31, 2020 | $2.37 | $1.95 | $1.13 - $2.36 | +21.54% | Beat | -9.5% | 10 | N/A | Apr 29, 2020 | $2.82B |
| Dec 31, 2019 | $2.86 | $2.80 | $2.76 - $2.82 | +2.14% | Beat | +13.5% | 15 | N/A | Feb 13, 2020 | $2.95B |
| Sep 30, 2019 | $2.90 | $2.85 | $2.81 - $2.88 | +1.75% | Beat | +5.8% | 16 | N/A | Oct 24, 2019 | $2.93B |
| Jun 30, 2019 | $2.93 | $2.92 | $2.82 - $3.05 | +0.34% | Beat | -1.7% | 20 | N/A | Jul 25, 2019 | $2.88B |
| Mar 31, 2019 | $2.62 | $2.54 | $2.49 - $2.59 | +3.15% | Beat | -5.8% | 18 | N/A | Apr 30, 2019 | $2.79B |
| Dec 31, 2018 | $2.52 | $2.49 | $2.41 - $2.53 | +1.20% | Beat | +2.9% | 18 | N/A | Feb 7, 2019 | $2.79B |
| Sep 30, 2018 | $2.74 | $2.89 | $2.78 - $2.93 | -5.19% | Miss | +11.4% | 18 | N/A | Oct 24, 2018 | $2.83B |
| Jun 30, 2018 | $2.98 | $2.92 | $2.72 - $3.18 | +2.05% | Beat | +20.6% | 17 | N/A | Jul 25, 2018 | $2.87B |
| Mar 31, 2018 | $2.78 | $2.63 | $2.56 - $2.75 | +5.70% | Beat | +25.2% | 16 | N/A | Apr 25, 2018 | $2.85B |
| Dec 31, 2017 | $2.45 | $2.38 | $2.35 - $2.43 | +2.94% | Beat | +14.0% | 18 | N/A | Feb 6, 2018 | $2.74B |
| Sep 30, 2017 | $2.46 | $2.39 | N/A | +2.93% | Beat | +9.3% | N/A | N/A | Oct 25, 2017 | $2.62B |
| Jun 30, 2017 | $2.47 | $2.41 | N/A | +2.49% | Beat | +6.9% | N/A | N/A | Jul 26, 2017 | $2.53B |
| Mar 31, 2017 | $2.22 | $2.20 | N/A | +0.91% | Beat | +9.9% | N/A | N/A | Apr 25, 2017 | $2.41B |
| Dec 31, 2016 | $2.15 | $2.13 | N/A | +0.94% | Beat | +8.6% | N/A | N/A | Feb 16, 2017 | $2.34B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $16.44, up 12.8% from the year before. It was $8.73 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $16.44 | +12.8% |
| Dec 31, 2024 | $14.57 | +4.7% |
| Dec 31, 2023 | $13.92 | -30.0% |
| Dec 31, 2022 | $19.89 | -30.2% |
| Dec 31, 2021 | $28.51 | +19.2% |
| Dec 31, 2020 | $23.91 | +111.4% |
| Dec 31, 2019 | $11.31 | +2.6% |
| Dec 31, 2018 | $11.02 | +14.8% |
| Dec 31, 2017 | $9.60 | +10.0% |
| Dec 31, 2016 | $8.73 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,800 words across 17 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,827 | 17 | |
| 2026Q2 | Jun 30, 2026 | 8,048 | 17 | |
| 2026Q1 | Mar 31, 2026 | 6,463 | 14 | |
| 2025Q4 | Dec 31, 2025 | 7,836 | 14 | |
| 2025Q3 | Sep 30, 2025 | 6,552 | 17 | |
| 2025Q2 | Jun 30, 2025 | 8,050 | 17 | |
| 2025Q1 | Mar 31, 2025 | 7,904 | 16 | |
| 2024Q4 | Dec 31, 2024 | 1,269 | 9 |
2026Q3 Earnings Call
Opening remarks
Dewey Steadman VP, Investor Relations Good morning, and welcome to LabCorp's Third Quarter 2026 Financial Results Webcast. With me today are Adam H. Schechter, our Chairman and Chief Executive Officer, and Julia Wang, Executive Vice President and Chief Financial Officer. This morning, in the events section of the LabCorp investor relations website at ir.labcorp.com, we posted both our press release and the supplemental financial presentation with additional information on our business and operations. We will also host a replay of this webcast on the IR website for one year. On today's webcast, we will focus on our adjusted non-GAAP results for the third quarter of 2026, our capital allocation strategy, and our updated financial guidance for the full year 2026. Our GAAP results and a reconciliation of the non-GAAP financial measures to the most comparable GAAP financial measures are available in today's earnings release and the supplemental financial presentation. Please see the use of adjusted measures section in the supplemental presentation for more information regarding our use of non-GAAP financial measures. In today's remarks, the term organic growth excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in the early development business. Our remarks will also include forward-looking statements, including but not limited to statements about our updated 2026 financial guidance and long-term financial outlook, and the related assumptions of each; the expected impact of various factors on our business, operating and financial results, cash flows, and financial condition; global economic and market conditions; our future business strategies; the expected savings, benefits, and synergies from acquisitions and other transactions and partnerships; and our potential opportunities for future growth. Each of these forward-looking statements is subject to change based upon various factors, many of which are beyond our control. More information is included in our most recent annual report on Form 10-K and subsequent quarterly reports on Forms 10-Q and in the company's other filings with the SEC. We have no obligation to provide any updates to these forward-looking statements, even if our expectations change. Now I will turn the call over to LabCorp's Chairman and CEO, Adam H. Schechter. Adam?
Adam H. Schechter Chairman and CEO Thank you, Dewey. Good morning, everyone. We appreciate you joining us today to review our third-quarter 2026 results. LabCorp delivered another strong quarter, with 7% revenue growth driven by volume, margin expansion across the enterprise, and 14.5% EPS growth. Our results reflect disciplined execution as we drive continued momentum in diagnostics and biopharma laboratory services. With these strong results, we are increasing our 2026 guidance. Before turning to the specifics of the quarter, I want to briefly address PAMA.
Frequently Asked Questions About LH
When is Labcorp Holdings's next earnings date?
Labcorp Holdings's next earnings report is expected for Feb 15, 2027.
Did LH beat earnings estimates last quarter?
Yes. Labcorp Holdings reported EPS of $4.78 for the quarter ended Sep 30, 2026, above the $4.65 estimate, a 2.80% surprise.
What EPS do analysts expect from LH next quarter?
The consensus EPS estimate for Labcorp Holdings for the quarter ending Dec 31, 2026 is $4.65 from 18 analysts, with estimates from $4.25 to $4.84.
How often does LH beat earnings estimates?
Labcorp Holdings beat the EPS estimate in each of the last 13 quarters, with an average surprise of +2.84%.
LH pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts